448964-30-5

Basic information

• Product Name: 5,6-Dihydro-2H-indeno[5,6-b]furan-7(3H)-one
• Synonyms: 5,6-Dihydro-2H-indeno[5,6-b]furan-7(3H)-one;7H-Indeno[5,6-b]furan-7-one, 2,3,5,6-tetrahydro-;2,3,5,6-Tetrahydro-7H-Indeno[5,6-B]Furan-7-One(WX625019)
• CAS NO: 448964-30-5
• Molecular Formula: C11H10O2
• Molecular Weight: 174.1959
• Mol File: 448964-30-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 336.6±42.0 °C(Predicted)
• Appearance: /
• Density: 1.288±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5,6-Dihydro-2H-indeno[5,6-b]furan-7(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6-Dihydro-2H-indeno[5,6-b]furan-7(3H)-one(448964-30-5)
• EPA Substance Registry System: 5,6-Dihydro-2H-indeno[5,6-b]furan-7(3H)-one(448964-30-5)

Safety Data

• Hazardous Substances Data: 448964-30-5(Hazardous Substances Data)

Usage

General Description

5,6-Dihydro-2H-indeno[5,6-b]furan-7(3H)-one, also known as dihydrobenzofuranone, is a chemical compound with a molecular formula of C13H10O2. It is a cyclic organic compound that contains a furan ring fused to an indene group, and it is commonly used as a building block in the synthesis of various pharmaceuticals, agrochemicals, and natural products. 5,6-Dihydro-2H-indeno[5,6-b]furan-7(3H)-one has shown potential biological activities, including antifungal, antibacterial, and anticancer properties. Additionally, it has been utilized in the development of new materials in the field of organic electronics and polymer science due to its unique structural and electronic properties.

Upstream product

• 496-16-2 2.3-dihydrobenzofuran 
• 55745-70-5 2,3-dihydro-benzofuran-5-carbaldehyde 
• 203505-84-4 3-(2,3-dihydro-1-benzofuran-5-yl)-2-propenoic acid 
• 215057-28-6 3-(2,3-dihydro-1-benzofuran-5-yl)propanoic acid 
• 198707-57-2 3-(2,3-dihydro-1-benzofuran-5-yl)prop-2-enoic acid 

Downstream Products

• 448964-31-6 2-(2,3,5,6-tetrahydro-7H-indeno[5,6-b]furan-7-ylidene)acetonitrile 
• 448964-32-7 2-(3,5,6,7-tetrahydro-2H-indeno[5,6-b]furan-7-yl)ethylamine 
• 1412270-66-6 C₂₂H₂₁N₂O₂⁽¹⁺⁾*Br^(1-) 
• 1412270-70-2 C₂₃H₂₃N₂O₃⁽¹⁺⁾*Br^(1-) 
• 1412271-07-8 C₂₃H₂₃N₂O₂⁽¹⁺⁾*Br^(1-) 
• 1412271-47-6 C₂₄H₂₅N₂O₂⁽¹⁺⁾*Br^(1-) 
• 1412271-59-0 C₂₄H₂₄BrN₂O₂⁽¹⁺⁾*Br^(1-) 
• 1412271-83-0 C₂₆H₂₃N₂O₂⁽¹⁺⁾*Br^(1-) 
• 1412271-87-4 C₂₇H₂₅N₂O₃⁽¹⁺⁾*Br^(1-) 
• 1412271-99-8 C₂₆H₂₂BrN₂O₂⁽¹⁺⁾*Br^(1-) 

Relevant articles and documents

NOVEL COMPOUNDS AND USES

The present invention relates to compounds of formula (I): wherein Q is O or S; R1 is a cyclic group substituted with at least one group X, wherein R1 may optionally be further substituted; X is any group comprising a carbonyl group; and R2 is a cyclic group substituted at the α-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the dual action of NLRP3 inhibition and the stimulation of insulin secretion.

SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME

ABSTRACT The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists

To develop a new therapeutic agent for sleep disorders, we synthesized a novel series of tricyclic indan derivatives and evaluated them for their binding affinity to melatonin receptors. In our previous paper, we proposed a conformation of the methoxy group favorable for the binding of the MT1 receptor. To fix the methoxy group in an active conformation, we decided to synthesize conformationally restricted tricyclic indan analogues with the oxygen atom in the 6-position incorporated into a furan, 1,3-dioxane, oxazole, pyran, morpholine, or 1,4-dioxane ring system. Among these compounds, indeno[5,4-b]furan analogues were found to be the most potent and selective MT1 receptor ligands and to have superior metabolic stability. The optimization of substituents led to (S)-(-)-22b, which showed very strong affinity for human MT1 (Ki = 0.014 nM), but no significant affinity for hamster MT3 (Ki = 2600 nM) or other neurotransmitter receptors. The pharmacological effects of (S)-(-)-22b were studied in experimental animals, and it was found that a dose of 0.1 mg/kg, po promoted a sleep in freely moving cats, as demonstrated by a decrease in wakefulness and increases in slow wave sleep and rapid eye movement sleep, which lasted for 6 h after administration. Melatonin (1 mg/kg, po) also had a sleep-promoting effect, though it lasted only 2 h. A new chiral method for the synthesis of (S)-(-)-22b starting from 60, which was prepared from 59 employing asymmetric hydrogenation with the (S)-2,2′-bis(diphenylphosphino)-1,1′-binaphthyl-Ru complex, was developed. (S)-(-)-22b (TAK-375) is currently under clinical trial for the treatment of insomnia and circadian rhythm disorders.